New hope for endometriosis sufferers: drug trial targets severe pain
NCT ID NCT05101317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called HMI-115 in 142 women with moderate-to-severe endometriosis pain. Over 12 weeks, researchers compared the drug to a placebo to see if it safely reduces pain during periods and pelvic pain. The goal is to find a new treatment option for this chronic condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instytut Matki i Dziecka
Warsaw, Masovian Voivodeship, Poland
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100703, China
-
Physicians' Research Options, LLC- Corner Canyon Clinic
Draper, Utah, 84020, United States
-
Specjalistyczna Poradnia Ginekologiczna Gabinet Ginekologiczny Dr med. Janusza Tomaszewskiego
Bialystok, Podlaskie Voivodeship, Poland
-
Tidewater Clinical Research/TPW
Norfolk, Virginia, 23502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can yoga ease the pain of endometriosis after surgery?
- Building a biological treasure trove to decode Women's health mysteries
- Gaming for health: could a video game empower endometriosis patients?
- Can a new formulation of an endometriosis drug match the standard?
- Can a glowing dye reveal a Woman's fertility after ovarian cyst surgery?
- Can we predict endometriosis recurrence and fertility outcomes?